

Amendments to the Claims

The following listing of claims replaces all prior versions of claims in the application:

- 1.(original) A salt of risperidone in solid state having a water solubility of at least 10 mg/ml.
- 2.(original) The salt according to claim 1, having a water solubility of at least 20 mg/ml.
- 3.(original) The salt according to claim 2, having a water solubility within the range of 20 to 200 mg/ml.
- 4.(original) The salt according to claim 1, wherein said salt is a pharmaceutically acceptable acid addition salt of risperidone.
- 5.(original) The salt according to claim 4, wherein said salt is an acid addition salt of risperidone with an acid selected from the group consisting of hydrochloric acid, methane sulfonic acid, benzene sulfonic acid, tartaric acid, maleic acid, malic acid, ethane disulfonic acid, lactic acid, acetic acid, and mandelic acid.
- 6.(original) The salt according to claim 4, wherein said salt is selected from the group consisting of risperidone dihydrochloride, risperidone mesylate, risperidone hemitartrate, risperidone hydrogenmaleate, risperidone (L)-hemimalate, risperidone hemiedisylate, risperidone (L)-lactate, risperidone acetate monohydrate, and risperidone (R)-mandelate.
- 7.(original) The salt according to claim 1, wherein said salt is in substantially isolated form.
- 8.(original) The salt according to claim 7, wherein said salt is at least 99% pure.
- 9.(original) The salt according to claim 1, wherein said salt is at least 99% pure.
- 10.(original) A pharmaceutical composition comprising the salt according to claim 1 and at least one pharmaceutically acceptable excipient.

11.(original) A process for making a solid state water soluble salt of risperidone, which comprises:
contacting a risperidone donor with a suitable acid in an organic solvent to form a water soluble risperidone salt; and
precipitating said risperidone salt from said solvent.

12.(original) The process according to claim 11, wherein said solvent is selected from the group consisting of an alcohol or an ester.

13.(original) The process according to claim 12, wherein said solvent is methanol or ethanol.

14.(original) The process according to claim 11, wherein said salt is selected from the group consisting of risperidone dihydrochloride, risperidone mesylate, risperidone hemitartrate, risperidone hydrogenmaleate, risperidone (L)-hemimalate, risperidone hemiedisylate, risperidone (L)-lactate, risperidone acetate monohydrate, and risperidone (R)-mandelate.

15.(original) A salt of risperidone selected from the group consisting of risperidone dihydrochloride, risperidone hydrogenmaleate, risperidone hemitartrate and risperidone hemimalate.

16.(currently amended) The salt according to claim 15, claim 17, wherein said salt is in solid state.

17.(currently amended) The salt according to claim 15, claim 17, wherein said salt is in dissolved form.

18.(currently amended) A pharmaceutical composition, comprising a salt according to claim 15 claim 17 and a pharmaceutically acceptable excipient.

19.(currently amended) The pharmaceutical composition according to claim 18,~~claim 20~~,
wherein said composition is an aqueous liquid or suspension.

20.(currently amended) The pharmaceutical composition according to claim 18, ~~claim 21~~,
wherein said composition is a solid dosage form.

21.(original) A method for treating psychotic disorders in a mammal, which comprises
administering an effective amount of a risperidone salt according to claim 1 to a
mammal in need thereof.

22.(currently amended) A method for treating psychotic disorders in a mammal, which
comprises administering an effective amount of a risperidone salt according to
claim 15 ~~claim 17~~ to a mammal in need thereof.